Project Grant R01CA296150
Award Date
12/13/24
Completion Date
11/30/29
Dollars Obligated
$668K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
This Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $639,964 to the University of Wisconsin System to conduct a pragmatic research study to evaluate implementation strategies for promoting smoking cessation treatment referrals among socioeconomically disadvantaged clients served by the Salvation Army.
The project aims to refine and test two implementation strategies: 1) a collaborative,...
The National Cancer Institute (NCI) awarded a $1,226,040 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Regents of the University of Minnesota to conduct a randomized clinical trial of a culturally-tailored suite of smoking cessation resources for American Indian persons.
The project aims to: 1) Co-create a culturally-aligned website, "Smokefree.gov for Natives," to serve as the landing page for online cessation treatment content and...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $625,201 to the University of Oklahoma Health Sciences Center to conduct a 5-year randomized clinical trial. The study aims to evaluate the effectiveness of combining the smoking cessation medication varenicline with nicotine lozenges, along with a smartphone-based medication adherence intervention, to improve smoking cessation rates among...
The National Cancer Institute (NCI) awarded a $653,951 Cooperative Agreement under the Cancer Cause and Prevention Research program (CFDA 93.393) to the University of Oklahoma Health Sciences Center. The purpose of this 5-year award is to implement and evaluate sustainable mobile health (mHealth) technology to optimize a smoking cessation program for people with HIV in Laos.
Specifically, the project will compare two strategies for delivering evidence-based smoking cessation interventions...
This $316,873 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will enable the development and pilot testing of a smartphone app version of the Libre del Cigarrillo smoking cessation intervention for Spanish-speaking smokers. The Libre del Cigarrillo intervention was previously validated in a nationwide randomized controlled trial, demonstrating high efficacy compared to usual care. This project aims to adapt the...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) is providing $757,913 to the Fred Hutchinson Cancer Center in Seattle, Washington to conduct a randomized controlled trial evaluating the efficacy and cost-effectiveness of providing a smoking cessation smartphone app (iCanQuit) combined with free nicotine replacement therapy (NRT) versus the app alone for Hispanic adults. The goal is to determine...
The National Cancer Institute (NCI) awarded a $728,006 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Chicago. The 5-year grant, with a start date of September 18, 2024, will fund a clinical trial to optimize the treatment of co-occurring smoking and unhealthy alcohol use among people with HIV in Nairobi, Kenya.
The trial will compare the effectiveness of an enhanced smoking cessation counseling program that also addresses alcohol use...
This Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, is for a $1,698,536 behavioral and digital intervention study to promote vaping cessation and prevent escalation of tobacco use among adolescents aged 14-18. The Primary Awardee, The General Hospital Corporation (Massachusetts General Hospital), will evaluate the effectiveness of the "QuitVaping" intervention, a fully remote, 12-session...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, will provide $885,824 to Health Research, Inc. at Roswell Park in Buffalo, NY from August 1, 2024 to July 31, 2026. The award will fund a research study to explore consumer responses to the FDA's recent authorizations allowing smokeless tobacco products to make modified risk claims in advertising. Specifically, the study will investigate 1) consumer exposure...
This $129,708 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support a 5-year study at Purdue University to examine the impact of local tobacco retail policies on sociodemographic disparities in tobacco use outcomes.
The key objectives of the study are to: 1) Describe and examine the impact of local tobacco retailer licensing laws and fees on differences in retailer density by race/ethnicity, income, and education; 2) Measure the...